Jefferies Remains Ultra-Bullish on Amarin (AMRN) Ahead of Commercialization Decision
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Fed: Nine Of 18 FOMC Participants Pencil In 2026 Rate Hike
- Delta Air Lines (DAL) Raises Quarterly Dividend 14.7% to $0.2150; 1% Yield
- Oil rises 1% on US-Iran deal doubts; IEA warns of supply glut
Did Amarin (AMRN) Just Thread the Needle or is There More NCE Heartache Ahead?
November 9, 2012 11:45 AM ESTAmarin Corporation (NASDAQ: AMRN) investors have been put through the wringer over the past few months. After gloriously winning FDA approval for Vascepa in July, shareholders have frighteningly watched gains slip away related to the ever-allusive NCE status. However, clues now suggest things are finally coming to a head.
During its quarterly conference call yesterday the company stated it is still evaluating three paths to commercialization of Vascepa: 1. an acquisition, 2. a strategic collaboration, 3. or self-commercialization (which could include third-party support). The company indicated... More
Amarin Corp Plc (AMRN) Posts Q3 adj.Loss of 26c/Share; Updates on Vascepa Approvals, Exclusivity
November 8, 2012 4:29 PM ESTAmarin Corp Plc (NASDAQ: AMRN) reported Q3 EPS of ($0.26), $0.04 worse than the analyst estimate of ($0.22).
Vascepa regulatory update
On July 26, 2012, the U.S. Food and Drug Administration (FDA) approved Vascepa (icosapent ethyl) capsules (formerly known as AMR101) as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (TG >500mg/dL) hypertriglyceridemia. The only reported adverse reaction with an incidence >2% and greater than placebo in Vascepa treated patients was arthralgia (2.3% for Vascepa, 1.0% for placebo). The approved label shows that Vascepa, compared to placebo, reduces TG's, Apo B, non-HDL-C,... More
